Cite
Kaminski H, Kamar N, Thaunat O, et al. Incidence of Cytomegalovirus Infection in Seropositive Kidney Transplant Recipients Treated with Everolimus : a randomized, open-labelled, multicentre phase 4 trial. Am J Transplant. 2022;doi: 10.1111/ajt.16946.
Kaminski, H., Kamar, N., Thaunat, O., Bouvier, N., Caillard, S., Garrigue, I., Anglicheau, D., Rérolle, J. P., Le Meur, Y., Durrbach, A., Bachelet, T., Savel, H., Coueron, R., Visentin, J., Del Bello, A., Pellegrin, I., Déchanet-Merville, J., Merville, P., Thiébaut, R., & Couzi, L. (2022). Incidence of Cytomegalovirus Infection in Seropositive Kidney Transplant Recipients Treated with Everolimus : a randomized, open-labelled, multicentre phase 4 trial. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, . https://doi.org/10.1111/ajt.16946
Kaminski, Hannah, et al. "Incidence of Cytomegalovirus Infection in Seropositive Kidney Transplant Recipients Treated with Everolimus : a randomized, open-labelled, multicentre phase 4 trial." American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons vol. (2022). doi: https://doi.org/10.1111/ajt.16946
Kaminski H, Kamar N, Thaunat O, Bouvier N, Caillard S, Garrigue I, Anglicheau D, Rérolle JP, Le Meur Y, Durrbach A, Bachelet T, Savel H, Coueron R, Visentin J, Del Bello A, Pellegrin I, Déchanet-Merville J, Merville P, Thiébaut R, Couzi L. Incidence of Cytomegalovirus Infection in Seropositive Kidney Transplant Recipients Treated with Everolimus : a randomized, open-labelled, multicentre phase 4 trial. Am J Transplant. 2022 Jan 06; doi: 10.1111/ajt.16946. Epub 2022 Jan 06. PMID: 34990047.
Copy
Download .nbib